Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Linn

Showing results (221-230 of 467) with videos related to

Pageof 47
Sort By:
International Journal of Cancer|November 30, 2020
Comprehensive trends in incidence, treatment, survival and mortality of first primary invasive breast cancer stratified by age, stage and receptor subtype in the Netherlands between 1989 and 2017Daniël J van der Meer, Iris Kramer, Marissa C van Maaren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2010
Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trialChristina M Schilder, Caroline Seynaeve, Louk V Beex, et al.
Cancer Treatment Reviews|February 5, 2023
Germline TP53 pathogenic variants and breast cancer: A narrative reviewEva Blondeaux, Luca Arecco, Kevin Punie, et al.
European Journal of Clinical Pharmacology|December 15, 2020
A real or apparent decrease in glomerular filtration rate in patients using olaparib?M A C Bruin, C M Korse, B van Wijnen, et al.
Breast Cancer Research : BCR|January 29, 2014
PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patientsKarin Beelen, Mark Opdam, Tesa M Severson, et al.
Breast Cancer Research and Treatment|May 15, 2013
Platform comparisons for identification of breast cancers with a BRCA-like copy number profilePhilip C Schouten, Ewald van Dyk, Linde M Braaf, et al.
Breast Cancer Research : BCR|January 23, 2014
Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatmentKarin Beelen, Mark Opdam, Tesa M Severson, et al.
Breast (Edinburgh, Scotland)|July 27, 2025
Prognostication and treatment predictions for estrogen receptor positive early-stage breast cancer: incorporating the 70-gene signature into the PREDICT prognostication modelEllen G Engelhardt, Mary Ann E Binuya, Paul D P Pharoah, et al.
Breast Cancer Research and Treatment|July 27, 2015
The prognostic value of the neoadjuvant response index in triple-negative breast cancer: validation and comparison with pathological complete response as outcome measureM Jebbink, E van Werkhoven, I A M Mandjes, et al.
International Journal of Cancer|February 4, 2021
A Phase I dose-escalation study of two cycles carboplatin-olaparib followed by olaparib monotherapy in patients with advanced cancerJill J J Geenen, Gwen M H E Dackus, Philip C Schouten, et al.
Pageof 47

Showing results (221-230 of 467) with videos related to

Sort By:
Pageof 47
International Journal of Cancer|November 30, 2020
Comprehensive trends in incidence, treatment, survival and mortality of first primary invasive breast cancer stratified by age, stage and receptor subtype in the Netherlands between 1989 and 2017Daniël J van der Meer, Iris Kramer, Marissa C van Maaren, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 10, 2010
Effects of tamoxifen and exemestane on cognitive functioning of postmenopausal patients with breast cancer: results from the neuropsychological side study of the tamoxifen and exemestane adjuvant multinational trialChristina M Schilder, Caroline Seynaeve, Louk V Beex, et al.
Cancer Treatment Reviews|February 5, 2023
Germline TP53 pathogenic variants and breast cancer: A narrative reviewEva Blondeaux, Luca Arecco, Kevin Punie, et al.
European Journal of Clinical Pharmacology|December 15, 2020
A real or apparent decrease in glomerular filtration rate in patients using olaparib?M A C Bruin, C M Korse, B van Wijnen, et al.
Breast Cancer Research : BCR|January 29, 2014
PIK3CA mutations, phosphatase and tensin homolog, human epidermal growth factor receptor 2, and insulin-like growth factor 1 receptor and adjuvant tamoxifen resistance in postmenopausal breast cancer patientsKarin Beelen, Mark Opdam, Tesa M Severson, et al.
Breast Cancer Research and Treatment|May 15, 2013
Platform comparisons for identification of breast cancers with a BRCA-like copy number profilePhilip C Schouten, Ewald van Dyk, Linde M Braaf, et al.
Breast Cancer Research : BCR|January 23, 2014
Phosphorylated p-70S6K predicts tamoxifen resistance in postmenopausal breast cancer patients randomized between adjuvant tamoxifen versus no systemic treatmentKarin Beelen, Mark Opdam, Tesa M Severson, et al.
Breast (Edinburgh, Scotland)|July 27, 2025
Prognostication and treatment predictions for estrogen receptor positive early-stage breast cancer: incorporating the 70-gene signature into the PREDICT prognostication modelEllen G Engelhardt, Mary Ann E Binuya, Paul D P Pharoah, et al.
Breast Cancer Research and Treatment|July 27, 2015
The prognostic value of the neoadjuvant response index in triple-negative breast cancer: validation and comparison with pathological complete response as outcome measureM Jebbink, E van Werkhoven, I A M Mandjes, et al.
International Journal of Cancer|February 4, 2021
A Phase I dose-escalation study of two cycles carboplatin-olaparib followed by olaparib monotherapy in patients with advanced cancerJill J J Geenen, Gwen M H E Dackus, Philip C Schouten, et al.
Pageof 47